Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Attenuation of the Apoptosis Stimulating Protein of TP53-1 (ASPP1) Is a Predictive Marker for Therapy Resistance and Overall Survival in Acute Myeloid Leukemia (AML)

Marcus M. Schittenhelm, Max Kaiser, Vasileia Tsintari, Gunnar Blumenstock, Balazs Györffy, Kerstin Maria Kampa-Schittenhelm

Blood (2021) 138 (Supplement 1): 1298.

https://doi.org/10.1182/blood-2021-152531

Published: 2021

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

ASPP2 k , a Dominant-Negative Splicing Variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2), Modulates Treatment Response Towards BCL-Signaling Inhibitors in Acute Myeloid Leukemia

Marcus M. Schittenhelm, Vasileia Tsintari, Rebecca Fröhlich, Kerstin Maria Kampa-Schittenhelm

Blood (2021) 138 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2021-152312

Published: 2021

Journal Articles

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140664

Published: 2020

Journal Articles

Dysregulation of the ASPP Protein Family (Apoptosis Stimulating Proteins of TP53) Is a Common Feature in High-Risk Acute Myeloid Leukemia (AML)

Kerstin Maria Kampa-Schittenhelm, MD, Max Kaiser, Mihada Bajrami Saipi, Bianca Walter, Gunnar Blumenstock, Lothar Kanz, Marcus M Schittenhelm, MD

Blood (2017) 130 (Supplement 1): 1231.

https://doi.org/10.1182/blood.V130.Suppl_1.1231.1231

Published: 2017

Journal Articles

Oncogenic Splicing of the Apoptosis-Stimulating Protein of p53-2 ( ASPP2 ) Is an Initiating Step in Leukemogenesis Facilitating Acquisition of Structural Genomic Mutations

Kerstin Maria Kampa-Schittenhelm, MD, Ulrike Mau-Holzmann, Charles Lopez, MD PhD, Marcus M. Schittenhelm

Blood (2016) 128 (22): 1555.

https://doi.org/10.1182/blood.V128.22.1555.1555

Published: 2016

Journal Articles

Attenuation of Apoptosis Stimulating Protein of p53-1 (ASPP1) Associates with Therapy Failure in Acute Myeloid Leukemia (AML)

Marcus M. Schittenhelm, Max Kaiser, Gunnar Blumenstock, Kerstin Maria Kampa-Schittenhelm, MD

Blood (2016) 128 (22): 1556.

https://doi.org/10.1182/blood.V128.22.1556.1556

Published: 2016

Journal Articles

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Blood (2016) 128 (22): 589.

https://doi.org/10.1182/blood.V128.22.589.589

Published: 2016

Journal Articles

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Kerstin Maria Kampa-Schittenhelm, MD, Hans-Joerg Buehring, Michael Bonin, Wichard Vogel, MD, Lothar Kanz, Prof. Dr. MD, Thomas Haverkamp, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2437.

https://doi.org/10.1182/blood.V126.23.2437.2437

Published: 2015

Journal Articles

Attenuation of Apoptosis-Stimulating Protein of p53-2 (ASPP2) Promotes IL-3-Independent Growth and Enhances Cytogenetic Abnormalities after Gamma-Irradiation in Mouse Hematopoietic Cells - Mimicking Early Leukemogenesis of Therapy-Associated Human AML

Kerstin Maria Kampa-Schittenhelm, MD, Ulrike Mau-Holzmann, Lothar Kanz, Prof. Dr. MD, Charles Lopez, MD PhD, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2460.

https://doi.org/10.1182/blood.V126.23.2460.2460

Published: 2015

Journal Articles

ASPP2 Attenuation Is an Early Step in Leukemogenesis Facilitating Acquisition of Mutations

Kerstin M Kampa-Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Charles Lopez, Marcus M Schittenhelm, Dr., MD

Blood (2014) 124 (21): 2221.

https://doi.org/10.1182/blood.V124.21.2221.2221

Published: 2014

Journal Articles

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

Marcus M Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Julia Frey, Katja Schuster, PhD, Abhijit Ramachandran, Lothar Kanz, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2014) 124 (21): 2230.

https://doi.org/10.1182/blood.V124.21.2230.2230

Published: 2014

Journal Articles

Heatshockproteins-60 and 90 Are Overexpressed In Leukemia Stem Cells and Stabilize Oncogene Signaling

Kerstin M Kampa-Schittenhelm, Dr., MD, Tanja Grandl, Figen Akmut, Barbara Illing, Marcus M Schittenhelm, Dr., MD

Blood (2013) 122 (21): 3952.

https://doi.org/10.1182/blood.V122.21.3952.3952

Published: 2013

Journal Articles

Methylation Of The 5’UTR Of Apoptosis Stimulating Protein Of p53-2 (ASPP2) Impairs Gene Expression and Associates With Aggressive Disease and Therapy Failure In Acute Leukemia

Marcus M Schittenhelm, Dr., MD, Barbara Illing, Figen Akmut, Gunnar Blumenstock, Konstanze Döhner, MD, Charles D Lopez, MD, PhD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2013) 122 (21): 3770.

https://doi.org/10.1182/blood.V122.21.3770.3770

Published: 2013

Journal Articles

Identification Of C-Terminal Truncated Splice Variants Of The Apoptosis-Stimulating Protein Of p53-2 (ASPP2) In Acute Leukemia Lacking The p53-Binding Site

Kerstin M Kampa-Schittenhelm, Dr.,, Barbara Illing, Figen Akmut, Michael Walter, PhD, Charles D Lopez, MD, PhD, Marcus M Schittenhelm, Dr.,

Blood (2013) 122 (21): 1270.

https://doi.org/10.1182/blood.V122.21.1270.1270

Published: 2013

Journal Articles

Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By Combination Approaches

Kerstin M Kampa-Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Marcus M Schittenhelm, Dr., MD

Blood (2013) 122 (21): 3856.

https://doi.org/10.1182/blood.V122.21.3856.3856

Published: 2013

Journal Articles

Heatshockprotein-60/90 Are Overexpressed in Leukemia Stem Cells and Stabilize Oncogene Signaling.

Kerstin M Kampa-Schittenhelm, Dr., MD, Lothar Kanz, MD, Marcus M Schittenhelm, Dr., MD

Blood (2012) 120 (21): 2472.

https://doi.org/10.1182/blood.V120.21.2472.2472

Published: 2012

Journal Articles

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Marcus M Schittenhelm, Dr., MD, Hartmut Doehner, MD, PhD, Konstanze Doehner, Lothar Kanz, MD, Michael C. Heinrich, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2012) 120 (21): 2474.

https://doi.org/10.1182/blood.V120.21.2474.2474

Published: 2012

Journal Articles

Attenuation of Apoptosis-Stimulating Protein of p53 2 (ASPP2 or TP53BP2) Associates with High Risk Disease and Therapy Failure in Acute Leukemia

Marcus M Schittenhelm, Dr., MD, Charles D Lopez, MD, PhD, Lothar Kanz, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2012) 120 (21): 1416.

https://doi.org/10.1182/blood.V120.21.1416.1416

Published: 2012

Journal Articles

Identification of Three Tyrosine Phosphorylation Sites in the p53 Binding Domain of Apoptosis-Stimulating p53 Protein 2 (ASPP2) That Are Differentially Phosphorylated in Response to Chemotherapy in Patient Derived AML Blasts

Kerstin M Kampa-Schittenhelm, Dr., MD, Charles D Lopez, MD, PhD, Marcus M Schittenhelm, Dr., MD

Blood (2011) 118 (21): 1396.

https://doi.org/10.1182/blood.V118.21.1396.1396

Published: 2011

NARROW

Attenuation of the Apoptosis Stimulating Protein of TP53-1 (ASPP1) Is a Predictive Marker for Therapy Resistance and Overall Survival in Acute Myeloid Leukemia (AML)

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

ASPP2 k , a Dominant-Negative Splicing Variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2), Modulates Treatment Response Towards BCL-Signaling Inhibitors in Acute Myeloid Leukemia

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Dysregulation of the ASPP Protein Family (Apoptosis Stimulating Proteins of TP53) Is a Common Feature in High-Risk Acute Myeloid Leukemia (AML)

Oncogenic Splicing of the Apoptosis-Stimulating Protein of p53-2 ( ASPP2 ) Is an Initiating Step in Leukemogenesis Facilitating Acquisition of Structural Genomic Mutations

Attenuation of Apoptosis Stimulating Protein of p53-1 (ASPP1) Associates with Therapy Failure in Acute Myeloid Leukemia (AML)

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Attenuation of Apoptosis-Stimulating Protein of p53-2 (ASPP2) Promotes IL-3-Independent Growth and Enhances Cytogenetic Abnormalities after Gamma-Irradiation in Mouse Hematopoietic Cells - Mimicking Early Leukemogenesis of Therapy-Associated Human AML

ASPP2 Attenuation Is an Early Step in Leukemogenesis Facilitating Acquisition of Mutations

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

Heatshockproteins-60 and 90 Are Overexpressed In Leukemia Stem Cells and Stabilize Oncogene Signaling

Methylation Of The 5’UTR Of Apoptosis Stimulating Protein Of p53-2 (ASPP2) Impairs Gene Expression and Associates With Aggressive Disease and Therapy Failure In Acute Leukemia

Identification Of C-Terminal Truncated Splice Variants Of The Apoptosis-Stimulating Protein Of p53-2 (ASPP2) In Acute Leukemia Lacking The p53-Binding Site

Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By Combination Approaches

Heatshockprotein-60/90 Are Overexpressed in Leukemia Stem Cells and Stabilize Oncogene Signaling.

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Attenuation of Apoptosis-Stimulating Protein of p53 2 (ASPP2 or TP53BP2) Associates with High Risk Disease and Therapy Failure in Acute Leukemia

Identification of Three Tyrosine Phosphorylation Sites in the p53 Binding Domain of Apoptosis-Stimulating p53 Protein 2 (ASPP2) That Are Differentially Phosphorylated in Response to Chemotherapy in Patient Derived AML Blasts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only